PMID- 24113628
OWN - NLM
STAT- MEDLINE
DCOM- 20140717
LR  - 20151119
IS  - 1473-5857 (Electronic)
IS  - 0268-1315 (Linking)
VI  - 29
IP  - 1
DP  - 2014 Jan
TI  - Paliperidone palmitate versus oral risperidone and risperidone long-acting 
      injection in patients with recently diagnosed schizophrenia: a tolerability and 
      efficacy comparison.
PG  - 45-55
LID - 10.1097/YIC.0000000000000006 [doi]
AB  - Early in the course of illness, patients with schizophrenia may be particularly 
      susceptible to adverse events (AEs). In this post-hoc, subgroup analysis of a 
      13-week, double-blind, double-dummy, multicenter study, patients recently 
      diagnosed with schizophrenia (</= 5 years) were administered once-monthly 
      flexible-dose paliperidone palmitate (PP) (n=161; initiation doses, 150 mg eq day 
      1 and 100 mg eq day 8) [PP doses can be expressed as milligram equivalents (mg 
      eq) of paliperidone or as milligrams (mg) of PP. 150 mg eq paliperidone=234 mg 
      PP; 100 mg eq paliperidone=156 mg PP. In the USA, dosing tends to be expressed in 
      mg] or oral risperidone [during initiation of risperidone long-acting injection 
      (RLAI) days 1-28] and biweekly flexible-dose RLAI (n=173; initial injection day 
      8). Assessments were performed at baseline and days 4, 15, 22, 36, 64, and 92. 
      Because of RLAI's release profile, data through day 22 correspond to oral 
      risperidone in the RLAI arm. During this period, the AE profile and onset of 
      efficacy of PP and oral risperidone were similar. The overall AE rates at week 13 
      for PP and RLAI were 54.7 and 50.3%, respectively, for any AE; 11.2 and 8.1% for 
      extrapyramidal symptom-related AEs; and 2.5 and 2.3% for prolactin-related AEs. 
      No significant differences in the mean weight change, most metabolic parameters, 
      or mean efficacy measures were observed at end point. In patients with recently 
      diagnosed schizophrenia, the tolerability and efficacy of PP and RLAI were 
      generally similar over 13 weeks.
FAU - Fu, Dong-Jing
AU  - Fu DJ
AD  - aMedical Affairs bMedical Information, Janssen Scientific Affairs, LLC 
      cBiostatistics, B&P, Janssen Research & Development, LLC, Titusville, New Jersey, 
      USA.
FAU - Bossie, Cynthia A
AU  - Bossie CA
FAU - Sliwa, Jennifer K
AU  - Sliwa JK
FAU - Ma, Yi-Wen
AU  - Ma YW
FAU - Alphs, Larry
AU  - Alphs L
LA  - eng
SI  - ClinicalTrials.gov/NCT00589914
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Isoxazoles)
RN  - 0 (Palmitates)
RN  - 9002-62-4 (Prolactin)
RN  - L6UH7ZF8HC (Risperidone)
RN  - R8P8USM8FR (Paliperidone Palmitate)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Diagnostic and Statistical Manual of Mental Disorders
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Isoxazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Muscle Rigidity/chemically induced/epidemiology
MH  - Paliperidone Palmitate
MH  - Palmitates/administration & dosage/adverse effects/*therapeutic use
MH  - Prolactin/blood
MH  - Psychiatric Status Rating Scales
MH  - Risperidone/administration & dosage/adverse effects/*therapeutic use
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
EDAT- 2013/10/12 06:00
MHDA- 2014/07/18 06:00
CRDT- 2013/10/12 06:00
PHST- 2013/10/12 06:00 [entrez]
PHST- 2013/10/12 06:00 [pubmed]
PHST- 2014/07/18 06:00 [medline]
AID - 10.1097/YIC.0000000000000006 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2014 Jan;29(1):45-55. doi: 
      10.1097/YIC.0000000000000006.